1. Home
  2. Faculty

Katie M. Larson Ode, MD, MS

Clinical Professor of Pediatrics-Endocrinology and Diabetes

Introduction

Dr. Larson Ode graduated Summa Cum Laude from Luther College in Decorah, IA. She obtained her MD from the University of Wisconsin Madison. Her residency in Categorical Pediatrics was at Rainbow Babies and Children's Hospital at Case Western University in Cleveland, Ohio. Her Fellowship in Pediatric Endocrinology and Master's in Clinical Research were obtained from the University of Minnesota. She has been on faculty at the University of Iowa since 2011.

Current Positions

  • Clinical Professor of Pediatrics - Endocrinology and Diabetes

Education

  • BA in Biology, Luther College, Decorah, Iowa
  • MD in Medicine, University of Wisconsin - Madison, Madison, Wisconsin
  • MS in Clinical Research, University of Minnesota, Minneapolis, Minnesota
  • Resident in Categorical Pediatrics, Case Western Reserve University, Rainbow Babies and Children's Hospital
  • Fellow in Pediatric Endocrinology, University of Minnesota, Minneapolis, Minnesota

Center, Program and Institute Affiliations

Research Interests

  • Glycemic Regulation in Infants and Children with Cystic Fibrosis
  • Clinical Management of Cystic Fibrosis Related Diabetes
  • Growth and development in early infancy related to maternal weight status
  • Early Pathophysiology of Cystic Fibrosis Related Diabetes
  • fasting islet hormones in normal infants and children
  • Outcomes of Cystic Fibrosis Related Diabetes

Licenses & Certifications

  • Pediatric Endocrinology, American Board of Pediatrics
  • American Board of Pediatrics
  • Minnesota Medical License (Inactive)
  • National Board of Medical Examiners
  • Iowa Medical License

Selected Publications

  • Abu-El-Haija M, Hornung L, Ellery K, Fishman DS, Gonska TY, Gariepy C, Lowe M, Ode KL, Maqbool A, Mascarenhas M, Morinville VD, Ooi CY, Perito ER, Schwarzenberg SJ, Sellers ZM, Zemel BS, Yuan Y, Wang F, Uc A, Kalkwarf HJ. Bone health in children with recurrent and chronic pancreatitis: A multi-center cross sectional analysis, Pancreatology, 2023, ISSN 1424-3903, https://doi.org/10.1016/j.pan.2023
  • Kienenberger ZE, Farber TO, Teresi ME, Milavetz F, Singh SB, Ode KL, Thoma T, Weiner RL, Burlage KR, Fischer AJ, "Patient and Caregiver Perceptions of Airway Clearance Methods Used for Cystic Fibrosis", Canadian Respiratory Journal, vol. 2023, Article ID 1422319,
  • Hicks R, Ode KL, Vigers T, Chan CL. A provider survey of cystic fibrosis related diabetes screening and management practices at North American CF centers. Front Endocrinol (Lausanne). 2023 May 18;14:1183288. doi: 10.3389/fendo.2023.1183288. PMID: 37274323; PMCID: PMC10232971
  • Putman MS, Norris AW, Hull RL, Rickels MR, Sussel L, Blackman SM, Chan CL, Ode KL, Daley T, Stecenko AA, Moran A, Helmick MJ, Cray S, Alvarez JA, Stallings VA, Tuggle KL, Clancy JP, Eggerman TL, Engelhardt JF, Kelly A. Cystic Fibrosis-Related Diabetes Workshop: Research Priorities Spanning Disease Pathophysiology, Diagnosis, and Outcomes. Diabetes Care. 2023 Jun 1;46(6):1112-1123. doi: 10.2337/dc23-0380. PMID: 37125948; PMCID: PMC10234745
  • Granados A, Chan CL, Moheet A, Vigers T, Arbeláez AM, Larson Ode K 2023). The impact of elexacaftor/tezacaftor/ivacaftor on body composition in a small cohort of youth with cystic fibrosis. Pediatr Pulmonol. Mar 17. doi: 10.1002/ppul.26388. Epub ahead of print. PMID: 36929859
  • Nichols DP, Paynter AC, Heltshe SL, Donaldson SH, Frederick CA, Freedman SD, Gelfond D, Hoffman LR, Kelly A, Narkewicz MR, Pittman JE, Ratjen F, Rosenfeld M, Sagel SD, Schwarzenberg SJ, Singh PK, Solomon GM, Stalvey MS, Clancy JP, Kirby S, Van Dalfsen JM, Kloster MH, Rowe SM, PROMISE Study Group (2022). Clinical effectiveness of elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis: A clinical trial. Am J Respir Crit Care Med 205(5):529-539 doi: 10.1164/rccm.202108-1986OC PMID: 34784492; PMCID: PMC8906485.
  • Granados, A., Chan, C. L., Ode, K. L., Moheet, A., Moran, A. & Holl, R. (2019). Cystic fibrosis related diabetes: Pathophysiology, screening and diagnosis. J Cystic Fibrosis 18 S3-S9. DOI: 10.1016/j.jcf.2019.08.016. PMID: 31679726.
  • Ode, K. L., Chan, C. L., Granados, A., Moheet, A., Moran, A. & Brennan, A. (2019). Cystic fibrosis related diabetes: Medical management. J Cystic Fibrosis 18 S10-S18. DOI: 10.1016/j.jcf.2019.08.003.. PMID: 31679720.
  • Sun, X., Yi, Y., Liang, B., Yang, Y., He, N., Larson Ode, K., Uc, A., Wang, K., Gibson-Corley, K. N., Engelhardt, J. F. & Norris, A. W. (2019). Incretin dysfunction and hyperglycemia in cystic fibrosis: Role of acyl-ghrelin. J Cystic Fibrosis 18 (4) 557-565. DOI: 10.1016/j.jcf.2019.01.010. PMID: 30738804.
  • Norris, A. W., Ode, K. L., Merjaneh, L., Sanda, S., Yi, Y., Sun, X., Engelhardt, J. F. & Hull, R. L. (2019). Survival in a bad neighborhood: pancreatic islets in cystic fibrosis. J Endocrinology. DOI: 10.1530/JOE-18-0468. PMID: 30759072. PMCID: PMC6675675.